Evidence map›Paper›PMID 30912119›Full record

ReviewClinical pharmacology and therapeutics2019

Pharmacodynamic Drug-Drug Interactions.

Jin Niu, Robert M Straubinger, Donald E Mager

Abstract readReview
In one paragraph

Review in Clinical pharmacology and therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
104citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

104 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Drug-drug interactions involving classic psychedelics: A systematic review.Journal of psychopharmacology (Oxford, England) · 2024
    Pooled it
  3. Guideline
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Response to Tutorial Drug-Drug Interactions by EM Sellers.Clinical and translational science · 2026
    Article
  17. Article
  18. Article
  19. Review
  20. Article

44 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jin NiuDepartment of Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, New York, USA.
Robert M StraubingerDepartment of Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, New York, USA.
Donald E MagerDepartment of Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, New York, USA.

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI CANDACE S JOHNSON · 1985 to 2026
$116.6M
Tumor priming sequences combined with novel nanoparticle drug carriers for enhanced therapeutic efficacy in pancreatic cancer: a tripartite USA/Northern Ireland/Republic of Ireland consortiumR01CA198096 · NCI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI CLYNES, MARTIN, MA, WEN WEE · 2015 to 2019
$2.2M
Large-scale proteome-wide analysis with high accuracy/precision to guide pancreatic cancer therapy developmentR21CA234775 · NCI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI MAGER, DONALD E, QU, JUN · 2019 to 2020
$399k
NCI NIH HHS P30 CA016056NCI NIH HHS R01 CA198096NCI NIH HHS R21 CA234775
6 · The paper itself

Abstract

Pharmacodynamic drug-drug interactions (DDIs) occur when the pharmacological effect of one drug is altered by that of another drug in a combination regimen. DDIs often are classified as synergistic, additive, or antagonistic in nature, albeit these terms are frequently misused. Within a complex pathophysiological system, the mechanism of interaction may occur at the same target or through alternate pathways. Quantitative evaluation of pharmacodynamic DDIs by employing modeling and simulation approaches is needed to identify and optimize safe and effective combination therapy regimens. This review investigates the opportunities and challenges in pharmacodynamic DDI studies and highlights examples of quantitative methods for evaluating pharmacodynamic DDIs, with a particular emphasis on the use of mechanism-based modeling and simulation in DDI studies. Advancements in both experimental and computational techniques will enable the application of better, model-informed assessments of pharmacodynamic DDIs in drug discovery, development, and therapeutics.

Indexed as

Models, BiologicalAnti-Infective AgentsAntineoplastic AgentsDrug Evaluation, PreclinicalDrug InteractionsHumansAnti-Infective AgentsAntineoplastic Agents

Identifiers

PMID30912119
PMCPMC6529235

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.